Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy

Home > News > Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy

Oligomerix > News > Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy